Insights on the Pulmonary/ Respiratory Drug Delivery Global Market to 2027 - Featuring 3M, Cipla and Omron Among Others - ResearchAndMarkets.com

The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, July 27, 2021
Information
Tags: 
Health, Pharmaceutical, Health sciences, Health care, Aerosols, Medical equipment, Nebulizer, Respiratory therapy, Health
Geotags: 
JAPAN, US, EUROPE, CHINA, INDIA, SOUTH KOREA, USA, AUSTRALIA, CANADA, GERMANY
Summary
Key Points: 
  • The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR
    The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020.
  • In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.


The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Pulmonary/ Respiratory Drug Delivery estimated at US$42.3 Billion in the year 2020, is projected to reach a revised size of US$59.8 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027.

Metered dose, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$41.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dry Powder segment is readjusted to a revised 5.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR

The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Nebulizer Segment to Record 5.4% CAGR

In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.

Select Competitors (Total 42 Featured):

  • 3M Company
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/lvvq83

Copyright: 
Copyright Business Wire 2021